fbpx

Check out the latest episodes of our Life Science and Food Industry Podcasts. Available everywhere!

X

Pfizer Recalls Blood Pressure Medication Over Nitrosamine Impurity + Jazz Pharma Announces New Manufacturing Facility for Cannabis-Based Medications – Xtalks Life Science Podcast Ep. 54

Pfizer Recalls Blood Pressure Medication Over Nitrosamine Impurity + Jazz Pharma Announces New Manufacturing Facility for Cannabis-Based Medications – Xtalks Life Science Podcast Ep. 54

In this episode, Ayesha discussed Pfizer’s voluntary recall of several lots of its blood pressure medication Accuretic and two generic versions of it due to higher than acceptable levels of a carcinogenic nitrosamine compound. The recall affects lots produced between November 2019 and March 2022. The editorial team discussed the increasing frequency of recalls of commonly prescribed drugs like blood pressure and diabetes medications. Should companies and regulators share more information about the steps being taken to address the issue of drug impurities?

The editorial team also talked about Jazz Pharmaceutical’s new $100 million manufacturing facility in the UK dedicated to the production of cannabis-based medicines. This includes the company’s bestselling epilepsy drug Epidiolex, which is the first FDA-approved cannabis-based medication. Construction on the facility has commenced and Jazz says it is committed to it being environmentally sustainable at all stages of development and use. Find out how Jazz is going green with its new cannabis-based drug manufacturing facility.

Listen on Apple Podcasts

Read the full articles here:

Accuretic Blood Pressure Drug and Two Generics Recalled by Pfizer Over Carcinogen Impurities

Jazz Pharma Announces $100 Million “Green” Manufacturing Plant for Cannabis-Based Medicines

The weekly podcast is available for streaming every Wednesday on SpotifyApple Music and wherever you stream your podcasts.

Subscribe to the Xtalks Life Science Podcast to never miss a new episode.